Skip to content

AERTS PHARMA

Active Private limited companyfounded 2007active for 19 yearsZavelstraat 22, 3520 ZonhovenKBO/BCE: BE 0886.207.737 subsidiary of

Lifetime

19 annual accounts with figures on one time axis
peak of €411,395 in 2024
€368,107▼ 10.5%
peak of €208,048 in 2024
€178,015▼ 14.4%
peak of €53,884 in 2025
€53,884unchanged
€988,676▲ 9.5%
peak of 1.7 FTE in 2016
1.6 FTEunchanged
Board1 name since 2009
1 director
Owners
99.46%
Documentsfilings and deeds
08-06-202653 days before the deadline
2025abbreviated format
Dividend €53,000Cash from €127,589 to €261,767

Key points

from the 2025 annual accounts

Equity

€53,884 =

AERTS PHARMA has made a profit in every financial year since 2007.

Debts

€988,676 95% of the balance sheet
Financial debts 11%Suppliers 23%Taxes and wages 2%Other 64%

Of this, €873,038 falls due within a year.

Filings

19 annual accounts since 2007
AprilJune31 JulyOctober2010201520202025

Seven of the last ten came late. The 2019 accounts came in latest, 34 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,326 companies had the same profile as AERTS PHARMA has now. Each dot stands for 4 companies, two years later.

95.1%
were still trading
3.2%
stopped another way
1.5%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,326 companies, not a prediction for AERTS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
  • 99.46%score equity €548,496 (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0886207737
acts as permanent representative “De exploitatie, huur en verhuur, van één of meer apotheken; Het verzorgen van vervangingen van en voor één of…” (deed in Dutch) · Gazette deed
Company renamed from APOTHEEK TACK to Aerts Pharma resigns as manager · appointed as manager · acts as permanent representative · Gazette deed
Incorporation Founded by · Capital of €18,600, 186 shares · appointed as manager · published on 16-01-2007 · Gazette deed
All 25 events

Comparable companies

same main activity, similar in size and age
Company
AERTS PHARMA Zonhoven €1.0m €368,107 5.2% 1.6
APOTHEEK SABINE DESIMPEL Moorslede €1.0m €328,806 70.3% 1.5
APOTHEEK HEIDE-HEUVEL Lommel €1.2m €362,980 77.5% 1.6
APOTHEEK KEVERS-REYNDERS Hechtel-Eksel €1.0m €383,458 37.5% 2
Apotheek Verachtert-Gysen Pelt €1.0m €401,112 78.2% 2
Apotheek VAN DIJCK Bree €0.9m €306,728 26.5% 1.7
APOTHEEK LANOO PASCALE Diepenbeek €1.3m €411,789 49.8% 1.8

These companies have the same main activity as AERTS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €931,000 and €1.3m, founded between 2004 and 2009.

Official details

Source: KBO
Status
Active since 08-01-2007Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.158.710.4523520 Zonhoven, since 07-01-2007
Financial year end
31 December
Peppol
Reachable since 25-06-2025
Company details

Annual accounts 2025

≈ €1.3mestimated
€1.0m▲ 9.0%
Employeeson 31-12-2025
2=
Filing
Filed on 08-06-2026, 53 days before the end of the filing period
Financials

Insights on AERTS PHARMA

AERTS PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €130,287 in 2007 to €368,107 in 2025.

The balance sheet grew most from 2008 to 2009 through fixed assets, financed with long-term debt.

holds 99.46% of the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about AERTS PHARMA

What is the company number of AERTS PHARMA?
The company number of AERTS PHARMA is 0886.207.737. The VAT number is the same number with BE in front: BE 0886.207.737.
Where is AERTS PHARMA based?
The registered office is at Zavelstraat 22, 3520 Zonhoven.Company details
What does AERTS PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of AERTS PHARMA?
AERTS PHARMA is a private limited company (BV).
When was AERTS PHARMA founded?
AERTS PHARMA was founded on 08-01-2007.
Is AERTS PHARMA still active?
Yes, AERTS PHARMA is an active enterprise in the KBO register.
How many employees does AERTS PHARMA have?
AERTS PHARMA had an average of 1.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does AERTS PHARMA fall under?
In its 2025 annual accounts, AERTS PHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of AERTS PHARMA?
The turnover in financial year 2025 is about €1.3m. This figure is estimated from the gross margin of €368,107 and 42 comparable companies (NACE 477). It probably lies between €1.0m and €1.8m.
Is AERTS PHARMA profitable?
In financial year 2025, AERTS PHARMA made a profit of €178,015.
Where can I find the annual accounts of AERTS PHARMA?
AERTS PHARMA filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of AERTS PHARMA due?
AERTS PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.